QNCX

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

Wall Street analysts forecast QNCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNCX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Quince Therapeutics Inc revenue for the last quarter amounts to -11.36M USD, increased 32.97 % YoY.

Quince Therapeutics Inc. EPS for the last quarter amounts to -10002000.00 USD, increased 36.90 % YoY.

Quince Therapeutics Inc (QNCX) has 36 emplpoyees as of December 15 2025.

Today QNCX has the market capitalization of 234.98M USD.